MRSA Testing Systems Market Wins Award

The global methicillin resistant staphylococcus aureus (MRSA) testing systems market is predicted to witness significant growth. In March 2016, Cepheid launched its Xpert MRSA NxG assay for the international markets, after the test won the CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices.

The growth is due to product launches by market players. as an example , in June 2017, Roche announced the launch of CE-IVD the cobas MRSA/SA macromolecule test to be used on the cobas Liat System for the qualitative detection and differentiation between methicillin-resistant Staphylococcus aureus (MRSA) infection and Staphylococcus aureus (SA) infection at the purpose of care.

MRSA and SA are both major sources of healthcare and community associated infections.

March 2016, Cepheid launched its Xpert MRSA NxG assay for the international markets, after the test won the CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices.

Further,in March 2016, Cepheid launched its Xpert MRSA NxG assay for the international markets, after the test won the CE-IVD status under the European Directive on

In Vitro Diagnostic Medical Devices.This diagnostic test is a next-generation version of the market-leading molecular diagnostic test for Methicillin-Resistant Staphyloccus aureus (MRSA).

Key Market Takeaways:

The Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems market is estimated to be valued at $105.08 million in 2020 and is expected to exhibit a CAGR of 10.5% during the forecast period (2020-2027).

The increasing prevalence of methicillin resistant staphylococcus aureus infection as well as approvals for products developed by market players are expected to drive growth of the methicillin resistant Staphylococcus aureus (MRSA) testing systems market.

Asia Pacific is expected to witness high demand for methicillin resistant Staphylococcus aureus (MRSA) testing systems owing to high prevalence of methicillin resistant Staphylococcus aureus (MRSA) infection in this region.

For instance, according to a study published in the Journal of Family Medicine and Primary care in 2018, prevalence of Staphylococcus aureus among children aged 5–15 years is 16%–52%, of which 4%–19% were MRSA infections in India.

Download the PDF Brochure

Key players operating in market are:

Key players operating in the methicillin resistant Staphylococcus aureus (MRSA) testing systems market are F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH, BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, Abbott Laboratories, Puritan Medical Products, Diatherix Eurofins, LLC, Arlington Scientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., Luminex Corporation, and R-Biopharm AG.

Regional Analysis:

The global market for methicillin resistant staphylococcus aureus (MRSA) testing systems is segmented into five key regions.

These regions are Europe, Asia Pacific, Middle East and Africa, Latin America, and North America.

Of these, currently the global methicillin resistant staphylococcus aureus (MRSA) testing systems market is being dominated by the regional segment of North America. The regional market is expected to continue to lead the global market in the coming years of the forecast period.

The Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems market is estimated to be valued at $105.08 million in 2020 and is expected to exhibit a CAGR of 10.5% during the forecast period (2020-2027).

The growth of the regional market can be mainly attributed to the growing number of companies operating in the region in coming years.

Buy Now the Research Report

Related Topics:

Orthopedic Devices Market Analysis

Growing incidences of orthopedic injuries such as osteoporosis, traumatic fractures,osteoarthritis, and rheumatoid arthritis along with surge in aging population worldwide drive the global orthopedic devices market. As a result, has increased the uptake of these devices worldwide, soar the market on the global platform.

HEALTHCARE CONTRACT RESEARCH OUTSOURCING MARKET

Healthcare Contract Research Outsourcing is conducted by pharmaceutical and medical device sectors for development of new drugs and medical devices.

Clinical trials form the key part of pharmaceutical drug and medical device development and in the current scenario clinical trials are conducted across multiple locations in various geographies.

Increasing cost and time required for drug development is expected to propel growth of the global healthcare contract research outsourcing market over the forecast period.

Get Report

Only $1/click

Submit Your Ad Here

Nirav Gokani

Digital Marketing Manager at <a href="http://coherentmarketinsights.com/">Coherent Market Insights </a> 000
https://www.coherentmarketinsights.com/phasexs/

Leave a Reply